Increased osteopontin plasma levels in multiple sclerosis patients correlate with bone-specific markers

Multiple Sclerosis

Volumn 16, Issue 4, 2010, Pages 443-449

  Vogt, Mario H J ^a   Kate, Joop Ten ^a   Drent, Roosmarie J M ^a   Polman, Chris H ^b   Hupperts, Raymond ^a  

^a Sittard Geleen Heerlen   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Bone; Multiple sclerosis; Osteopontin

Indexed keywords

25 HYDROXYVITAMIN D; BIOLOGICAL MARKER; CARBOXY TERMINAL TELOPEPTIDE; IMMUNOGLOBULIN G; MESSENGER RNA; OSTEOPONTIN; 25-HYDROXYVITAMIN D; COLLAGEN TYPE 1; COLLAGEN TYPE I TRIMERIC CROSS LINKED PEPTIDE; COLLAGEN TYPE I TRIMERIC CROSS-LINKED PEPTIDE; DRUG DERIVATIVE; OSTEOCALCIN; PEPTIDE; SPP1 PROTEIN, HUMAN; VITAMIN D;

ARTICLE; BLOOD SAMPLING; BONE METABOLISM; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; HUMAN; HUMAN CELL; IMMUNOMODULATION; MULTIPLE SCLEROSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; QUANTITATIVE ANALYSIS; BLOOD; CASE CONTROL STUDY; CLINICAL TRIAL; GENETICS; MULTICENTER STUDY; NETHERLANDS; UPREGULATION;

BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; COLLAGEN TYPE I; HUMANS; IMMUNOGLOBULIN G; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NETHERLANDS; OSTEOCALCIN; OSTEOPONTIN; PEPTIDES; RNA, MESSENGER; UP-REGULATION; VITAMIN D;

EID: 77954671743     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458509359723     Document Type: Article

References (33)

1. Steinman L. A molecular trio in relapse and remission in multiple sclerosis. Nat Rev Immunol 2009;9:440-447.
2. Chabas D, Baranzini SE, Mitchell D, et al. The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 2001;294:1731-1735.
3. Vogt MH, Lopatinskaya L, Smits M, et al. Elevated osteopontin levels in active relapsing-remitting multiple sclerosis. Ann Neurol 2003;53:819-822.
4. Comabella M, Pericot I, Goertsches R, et al. Plasma osteopontin levels in multiple sclerosis. J Neuroimmunol 2005;158:231-239.
5. Vogt MH, Floris S, Killestein J, et al. Osteopontin levels and increased disease activity in relapsing-remitting multiple sclerosis patients. J Neuroimmunol 2004;155:155-160.
6. Chowdhury SA, Lin J, Sadiq SA. Specificity and correlation with disease activity of cerebrospinal fluid osteopontin levels in patients with multiple sclerosis. Arch Neurol 2008;65:232-235.
7. Braitch M, Nunan R, Niepel G, et al. Increased osteopontin levels in the cerebrospinal fluid of patients with multiple sclerosis. Arch Neurol 2008;65:633-635.
8. Qin C, Baba O, Butler WT. Post-translational modifications of sibling proteins and their roles in osteogenesis and dentinogenesis. Crit Rev Oral Biol Med 2004;15:126-136.
9. Ross FP, Chappel J, Alvarez JI, et al. Interactions between the bone matrix proteins osteopontin and bone sialoprotein and the osteoclast integrin alpha v beta 3 potentiate bone resorption. J Biol Chem 1993;268:9901-9907.
10. Asou Y, Rittling SR, Yoshitake H, et al. Osteopontin facilitates angiogenesis, accumulation of osteoclasts, and resorption in ectopic bone. Endocrinology 2001;142:1325-1332.
11. Mazzali M, Kipari T, Ophascharoensuk V, et al. Osteopontin-a molecule for all seasons. QJM 2002;95:3-13.
12. Denhardt DT, Noda M, O'Regan AW, et al. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest 2001;107:1055-1061.
13. Ashkar S, Weber GF, Panoutsakopoulou V, et al. Eta-1 (osteopontin) : an early component of type-1 (cell-mediated) immunity. Science 2000;287:860-864.
14. Hur EM, Youssef S, Haws ME, et al. Osteopontin-induced relapse and progression of autoimmune brain disease through enhanced survival of activated T cells. Nat Immunol 2007;8:74-83.
15. Murugaiyan G, Mittal A, Weiner HL. Increased osteopontin expression in dendritic cells amplifies IL-17 production by CD4+ T cells in experimental autoimmune encephalomyelitis and in multiple sclerosis. J Immunol 2008;181:7480-7488.
16. Patarca R, Freeman GJ, Singh RP, et al. Structural and functional studies of the early T lymphocyte activation 1 (Eta-1) gene. Definition of a novel T cell-dependent response associated with genetic resistance to bacterial infection. J Exp Med 1989;170:145-161.
17. O'Regan A, Berman JS. Osteopontin: a key cytokine in cell-mediated and granulomatous inflammation. Int J Exp Pathol 2000;81:373-390.
18. McDonald WI, Compston A, Edan G, et al. Recommended criteria for multiple sclerosis: guidelines from the international Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-127.
19. Zhao C, Fancy SP, Ffrench-Constant C, Franklin RJ. Osteopontin is extensively expressed by macrophages following CNS demyelination but has a redundant role in remyelination. Neurobiol Dis 2008;31:209-217.
20. Lindberg RLP, Kappos L. Transcriptional profiling of multiple sclerosis: towards improved diagnosis and treatment. Expert Rev Mol Diagn 2006;6:843-855.
21. Bomprezzi R, Ringner M, Kim S, et al. Gene expression profile in multiple sclerosis patients and healthy controls: identifying pathways relevant to disease. Hum Mol Genet 2003;12:2191-2199.
22. Tuzun S, Altintas A, Karacan I, et al. Bone status in multiple sclerosis: beyond corticosteroids. Mult Scler 2003;9:600-604.
23. Weinstock-Guttman B, Gallagher E, Baier M, et al. Risk of bone loss in men with multiple sclerosis. Mult Scler 2004;10:170-175.
24. Smolders J, Menheere P, Kessels A, et al. Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis. Mult Scler 2008;14:1220-1224.
25. Soilu-Hanninen M, Laaksonen M, Laitinen I, et al. A longitudinal study of serum 25-hydroxyvitamin D and intact parathyroid hormone levels indicate the importance of vitamin D and calcium homeostasis regulation in multiple sclerosis. J Neurol Neurosurg Psychiatry 2008;79:152-157.
26. Smolders J, Damoiseaux J, Menheere P, et al. Vitamin D as an immune modulator in multiple sclerosis. J Neuroimmunol 2008;194:7-17.
27. Rieckmann P, Albrecht M, Kitze B, et al. Tumor necrosis factor-alpha messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity. Ann Neurol 1995;37:82-88.
28. Azuma Y, Kaji K, Katogi R, et al. Tumor necrosis factor-alpha induces differentiation of and bone resorption by osteoclasts. J Biol Chem 2000;275:4858-4864.
29. Gravallese EM. Osteopontin: a bridge between bone and the immune system. J Clin Invest 2003;112:147-149.
30. Cheng X, Kinosaki M, Murali R, Greene MI. The TNF receptor superfamily: role in immune inflammation and bone formation. Immunol Res 2003;27:287-294.
31. Nakashima T, Takayanagi H. Osteoimmunology: crosstalk between the immune and bone systems. J Clin Immunol 2009;29:555-567.
32. Zhu WH, Lu CZ, Huang YM, Link H, Xiao BG. A putative mechanism on remission of multiple sclerosis during pregnancy: estrogen-induced indoleamine 2, 3-dioxygenase by dendritic cells. Mult Scler 2007;13:33-40.
33. Matarese G, Carrieri PB, La Cava A, et al. Leptin increase in multiple sclerosis associates with reduced number of CD4 (+) CD25+ regulatory T cells. Proc Natl Acad Sci U S A 2005;102:5150-5155.